While the EPS miss might concern some investors, the substantial beat on revenue estimates and the impressive year-over-year sales growth are likely to be viewed positively. The significant increase in sales suggests strong demand for Cue Biopharma's products and operational growth, which could lead to a positive short-term impact on the stock price.